{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:24:48Z","timestamp":1788283488998,"version":"build-2803163510"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23AA2003"],"award-info":[{"award-number":["23AA2003"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["24AA2006"],"award-info":[{"award-number":["24AA2006"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["20H03907"],"award-info":[{"award-number":["20H03907"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["21H03159"],"award-info":[{"award-number":["21H03159"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["21K08123"],"award-info":[{"award-number":["21K08123"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To investigate the clinical significance of the modification of the kidney protective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors by baseline body mass index (BMI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We included individuals with SGLT2 inhibitors or dipeptidyl peptidase-4 (DPP4) inhibitors newly prescribed for type 2 diabetes using a nationwide epidemiological cohort and performed propensity score matching (1:2). The primary outcome was the annual eGFR decline, assessed using a linear mixed-effects model, compared between individuals with SGLT2 inhibitors and DPP4 inhibitors. We investigated the interaction effect of BMI at the time of prescription using a three-knot restricted cubic spline model. We analysed 2165 individuals with SGLT2 inhibitor prescriptions and 4330 individuals with DPP4 inhibitor prescriptions. Overall, the annual decline in eGFR was less pronounced in the group treated with SGLT2 inhibitors than in those treated with DPP4 inhibitors (\u22121.34\u00a0mL\/min\/1.73 m2 vs. \u22121.49\u00a0mL\/min\/1.73 m2). The advantage of SGLT2 inhibitors in mitigating eGFR decline was augmented in the individuals with higher BMI (P-value for interaction 0.0017). Furthermore, even upon adjusting the definition of outcomes to encompass a 30 or 40% reduction in eGFR, the potential advantages of SGLT2 inhibitors over DPP4 inhibitors persisted, with a trend of augmented effects with higher BMI. This interaction effect was evident in the individuals with preserved kidney function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our nationwide epidemiological study substantiated the improved kidney outcomes in the SGLT2 inhibitor users compared with the DPP4 inhibitor users across a wide range of BMI, which was pronounced for individuals with higher BMI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvae094","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T23:30:34Z","timestamp":1734132634000},"page":"155-163","source":"Crossref","is-referenced-by-count":8,"title":["Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3757-3959","authenticated-orcid":false,"given":"Takahiro","family":"Jimba","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2553-6170","authenticated-orcid":false,"given":"Hidehiro","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033 ,","place":["Japan"]},{"name":"Department of Advanced Cardiology, The University of Tokyo , Tokyo 113-0013 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033 ,","place":["Japan"]},{"name":"Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health , Saitama 351-0104 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo , Tokyo 113-0013 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Azegami","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine , Tokyo 160-0016 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Ko","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhito","family":"Fujiu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033 ,","place":["Japan"]},{"name":"Department of Advanced Cardiology, The University of Tokyo , Tokyo 113-0013 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine , Tokyo 160-0016 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yokoo","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-0939","authenticated-orcid":false,"given":"Koichi","family":"Node","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University , Saga 840-8502 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0714-7182","authenticated-orcid":false,"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033 ,","place":["Japan"]},{"name":"Department of Frontier Cardiovascular Science, Graduate School of Medicine, The University of Tokyo , Tokyo 113-0013 ,","place":["Japan"]},{"name":"International University of Health and Welfare , Tokyo 324-8501 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasunaga","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo , Tokyo 113-0013 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7401-2934","authenticated-orcid":false,"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine , Tokyo 113-0013 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The University of Tokyo , 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"2025031314304660500_bib1","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2025031314304660500_bib2","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2025031314304660500_bib3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2025031314304660500_bib4","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMc1712572","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2025031314304660500_bib5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.kint.2016.02.039","article-title":"Bariatric surgery is associated with improvement in kidney outcomes","volume":"90","author":"Chang","year":"2016","journal-title":"Kidney Int"},{"key":"2025031314304660500_bib6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000513664","article-title":"Effect of an intensive weight-loss lifestyle intervention on kidney function: a randomized controlled trial","volume":"52","author":"D\u00edaz-L\u00f3pez","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025031314304660500_bib7","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1002\/ejhf.2308","article-title":"Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index","volume":"23","author":"Adamson","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025031314304660500_bib8","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","article-title":"Dapagliflozin for heart failure according to body mass index: the DELIVER trial","volume":"43","author":"Adamson","year":"2022","journal-title":"Eur Heart J"},{"key":"2025031314304660500_bib9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The E-KCG","year":"2023","journal-title":"N Engl J Med"},{"key":"2025031314304660500_bib10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial","volume":"12","author":"Staplin","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025031314304660500_bib11","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/dom.14641","article-title":"Quetelet (body mass) index and effects of dapagliflozin in chronic kidney disease","volume":"24","author":"Chertow","year":"2022","journal-title":"Diabetes Obesity Metab"},{"key":"2025031314304660500_bib12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.31662\/jmaj.2021-0189","article-title":"Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people","volume":"5","author":"Okada","year":"2022","journal-title":"JMA J"},{"key":"2025031314304660500_bib13","doi-asserted-by":"publisher","first-page":"E52","DOI":"10.1055\/a-1981-2946","article-title":"Comparison of bleeding following gastrointestinal endoscopic biopsy in patients treated with and without direct oral anticoagulants","volume":"11","author":"Konishi","year":"2023","journal-title":"Endosc Int Open"},{"key":"2025031314304660500_bib14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s00134-022-06941-5","article-title":"Association between COVID-19 pandemic and mental disorders in spouses of intensive care unit patients","volume":"49","author":"Ohbe","year":"2023","journal-title":"Intensive Care Med"},{"key":"2025031314304660500_bib15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10384-022-00969-2","article-title":"Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan","volume":"67","author":"Hashimoto","year":"2023","journal-title":"Jpn J Ophthalmol"},{"key":"2025031314304660500_bib16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2025031314304660500_bib17","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2337\/dci22-0047","article-title":"Metformin and cancer: solutions to a real-world evidence failure","volume":"46","author":"Yu","year":"2023","journal-title":"Diabetes Care"},{"key":"2025031314304660500_bib18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.diabet.2020.01.002","article-title":"Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: a systematic review of randomized controlled trials","volume":"46","author":"Scheen","year":"2020","journal-title":"Diabetes Metab"},{"key":"2025031314304660500_bib19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"2025031314304660500_bib20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"2025031314304660500_bib21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/jdi.13636","article-title":"Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type\u20092 diabetes in Japan","volume":"13","author":"Bouchi","year":"2022","journal-title":"J Diabetes Invest"},{"key":"2025031314304660500_bib22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.kint.2022.05.031","article-title":"Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors","volume":"102","author":"Suzuki","year":"2022","journal-title":"Kidney Int"},{"key":"2025031314304660500_bib23","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1111\/dom.15561","article-title":"Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: a propensity-score matching study","volume":"26","author":"Suzuki","year":"2024","journal-title":"Diabetes Obesity Metab"},{"key":"2025031314304660500_bib24","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.1111\/dom.15808","article-title":"Body weight change associated kidney outcomes of sodium-glucose cotransporter new users","volume":"26","author":"Jimba","year":"2024","journal-title":"Diabetes Obesity Metab"},{"key":"2025031314304660500_bib25","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/dom.14415","article-title":"Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: a subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia","volume":"23","author":"Ji","year":"2021","journal-title":"Diabetes Obesity Metab"},{"key":"2025031314304660500_bib26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41392-023-01400-z","article-title":"Diabetic vascular diseases: molecular mechanisms and therapeutic strategies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae094\/61711688\/pvae094.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/2\/155\/61711688\/pvae094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/2\/155\/61711688\/pvae094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T10:31:01Z","timestamp":1741861861000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/2\/155\/7993358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,3]]},"published-print":{"date-parts":[[2025,3,13]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae094","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,2,3]]}}}